CX Institutional’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $159K | Buy |
302
+22
| +8% | +$11.6K | 0.01% | 688 |
|
|
2025
Q1 | $178K | Sell |
280
-18
| -6% | -$11.4K | 0.01% | 630 |
|
|
2024
Q4 | $212K | Sell |
298
-11
| -4% | -$7.84K | 0.01% | 507 |
|
|
2024
Q3 | $325K | Buy |
309
+7
| +2% | +$7.36K | 0.01% | 450 |
|
|
2024
Q2 | $317K | Buy |
302
+2
| +0.7% | +$2.1K | 0.01% | 449 |
|
|
2024
Q1 | $289K | Sell |
300
-15
| -5% | -$14.4K | 0.01% | 465 |
|
|
2023
Q4 | $277K | Buy |
315
+4
| +1% | +$3.51K | 0.01% | 425 |
|
|
2023
Q3 | $256K | Buy |
311
+30
| +11% | +$24.7K | 0.01% | 433 |
|
|
2023
Q2 | $202K | Sell |
281
-18
| -6% | -$12.9K | 0.01% | 501 |
|
|
2023
Q1 | $246K | Buy |
299
+12
| +4% | +$9.89K | 0.01% | 439 |
|
|
2022
Q4 | $207K | Buy |
+287
| New | +$207K | 0.01% | 490 |
|
|
2022
Q3 | – | Sell |
-154
| Closed | -$91K | – | 986 |
|
|
2022
Q2 | $91K | Buy |
+154
| New | +$91K | 0.01% | 561 |
|
|
2021
Q4 | – | Sell |
-133
| Closed | -$80K | – | 784 |
|
|
2021
Q3 | $80K | Sell |
133
-5
| -4% | -$3.01K | 0.01% | 489 |
|
|
2021
Q2 | $77K | Buy |
138
+53
| +62% | +$29.6K | 0.01% | 487 |
|
|
2021
Q1 | $40K | Buy |
85
+6
| +8% | +$2.82K | ﹤0.01% | 538 |
|
|
2020
Q4 | $38K | Sell |
79
-2
| -2% | -$962 | ﹤0.01% | 493 |
|
|
2020
Q3 | $45K | Buy |
81
+1
| +1% | +$556 | ﹤0.01% | 398 |
|
|
2020
Q2 | $50K | Buy |
80
+19
| +31% | +$11.9K | 0.01% | 339 |
|
|
2020
Q1 | $30K | Buy |
61
+36
| +144% | +$17.7K | ﹤0.01% | 340 |
|
|
2019
Q4 | $9K | Hold |
25
| – | – | ﹤0.01% | 445 |
|
|
2019
Q3 | $7K | Sell |
25
-3
| -11% | -$840 | ﹤0.01% | 521 |
|
|
2019
Q2 | $9K | Buy |
28
+2
| +8% | +$643 | ﹤0.01% | 509 |
|
|
2019
Q1 | $11K | Buy |
26
+22
| +550% | +$9.31K | ﹤0.01% | 450 |
|
|
2018
Q4 | $1K | Buy |
+4
| New | +$1K | ﹤0.01% | 508 |
|